Key result
In patients undergoing left atrial appendage occlusion, HFrEF was associated with a higher risk of composite in-hospital major adverse events (6.0% vs. 5.0%; adjusted OR 1.23; 95% CI 1.09-1.40).
Why the study?
Patients with HFrEF were excluded from major trials of left atrial appendage occlusion, leaving outcomes in this population unclear.
Does the presence of HFrEF increase the risk of adverse events and readmissions in patients undergoing left atrial appendage occlusion compared to those without HFrEF?
Cohort
Yes
Does the presence of HFrEF increase the risk of adverse events and readmissions in patients undergoing left atrial appendage occlusion compared to those without HFrEF?
Odds Ratio: 1.23 (95% CI 1.09–1.4)
Absolute Event Rate: 6% vs 5%
p-value: p=0.001
In patients undergoing left atrial appendage occlusion, the presence of HFrEF is associated with significantly higher risks of in-hospital major adverse events and 6-month readmissions.
BACKGROUND: Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from major trials of left atrial appendage occlusion (LAAO). AIM: The objective of this study was to describe this population and evaluate outcomes after LAAO in patients with and without HFrEF. METHODS: Patients with and without HFrEF undergoing LAAO were identified in the Nationwide Readmissions Database from 2016 to 2020. Outcomes of interest were major in-hospital adverse events (death, stroke, pericardial effusion, tamponade, pericardial window, transfusion) and 6-month readmissions (any readmission, heart failure readmission, death/stroke readmission). To account for differences between patients with and without HFrEF, outcomes were evaluated using risk-adjusted logistic regression models and risk-adjusted Cox proportional hazards models. RESULTS: -VASC score was 3.8 ± 1.3 in the HFrEF group and 3.7 ± 1.4 in those without HFrEF. HFrEF was associated with a higher risk of composite in-hospital major adverse events (6.0% vs. 5.0%, adjusted OR 1.23 [95% CI 1.09-1.40], p = 0.001) and a higher risk of 6-month all-cause readmission (adjusted HR 1.18 [95% CI 1.08-1.28], p < 0.001), heart failure readmission (adjusted HR 1.59 [95% CI 1.46-1.72], p < 0.001), and readmission with death or stroke (adjusted HR 1.27 [95% CI 1.03-1.57], p = 0.001). CONCLUSION: One out of nine patients treated with LAAO in the United States has HFrEF, which is associated with a higher risk of major in-hospital complications and hospital readmission.
No takes yet. Share an insight, caveat, or question.
Ubaid et al. (2026) conducted a cohort in Patients undergoing left atrial appendage occlusion (LAAO). Heart failure with reduced ejection fraction (HFrEF) vs. Without HFrEF was evaluated on Composite in-hospital major adverse events (OR 1.23, 95% CI 1.09-1.40, p=0.001). In patients undergoing left atrial appendage occlusion, HFrEF was associated with a higher risk of composite in-hospital major adverse events (6.0% vs. 5.0%; adjusted OR 1.23; 95% CI 1.09-1.40).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: